{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:50:54Z","timestamp":1790635854309,"version":"4.1.0"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1093\/cvr\/cvz020","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T01:48:44Z","timestamp":1548380924000},"page":"878-894","source":"Crossref","is-referenced-by-count":67,"title":["Cardiac arrhythmia considerations of hormone cancer therapies"],"prefix":"10.1093","volume":"115","author":[{"given":"Mary","family":"Barber","sequence":"first","affiliation":[{"name":"Department of Medicine and Clinical Pharmacology, Cardio-Oncology Program, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Sorbonne Universit\u00e9, INSERM CIC Paris-Est, AP-HP, ICAN, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris F-75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Wassermann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris F-75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris F-75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Sorbonne Universit\u00e9, INSERM CIC Paris-Est, AP-HP, ICAN, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris F-75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Pharmacology, Cardio-Oncology Program, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN, USA"},{"name":"Department of Pharmacology, Sorbonne Universit\u00e9, INSERM CIC Paris-Est, AP-HP, ICAN, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris F-75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B2","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2009.27.4290","article-title":"Influence of sex hormones on cancer progression","volume":"28","author":"Folkerd","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0092-8674(88)90017-7","article-title":"The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer","volume":"55","author":"Kumar","year":"1988","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B4","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1016\/S0021-9258(17)41801-1","article-title":"Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity","volume":"269","author":"Le Goff","year":"1994","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B5","doi-asserted-by":"crossref","first-page":"22296","DOI":"10.1074\/jbc.274.32.22296","article-title":"Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex","volume":"274","author":"Rogatsky","year":"1999","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B6","doi-asserted-by":"crossref","first-page":"e1000658.","DOI":"10.1371\/journal.pcbi.1000658","article-title":"Acute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation study","volume":"6","author":"Yang","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B7","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004880","article-title":"Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation","volume":"6","author":"Sharma","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of torsades de pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","article-title":"Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B14","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1210\/jc.2016-1877","article-title":"Complex influence of gonadotropins and sex steroid hormones on QT interval duration","volume":"101","author":"Abehsira","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B16","doi-asserted-by":"crossref","first-page":"e0181875.","DOI":"10.1371\/journal.pone.0181875","article-title":"GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, \u201cGENEREPOL study\u201d: Lack of common variants with large effect sizes","volume":"12","author":"Salem","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.acvd.2016.12.011","article-title":"Fast, accurate and easy-to-teach QT interval assessment: the triplicate concatenation method","volume":"110","author":"Saque","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B18","doi-asserted-by":"crossref","first-page":"17B","DOI":"10.1016\/0002-9149(93)90035-B","article-title":"Rate-corrected QT interval: techniques and limitations","volume":"72","author":"Funck-Brentano","year":"1993","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.acvd.2016.12.011","article-title":"Fast, accurate and easy-to-teach QT interval assessment: the triplicate concatenation method","volume":"110","author":"Saque","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.113.007765","article-title":"Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current","volume":"130","author":"Yang","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/jpet.117.246157","article-title":"Inhibition of the alpha-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic","volume":"365","author":"Yang","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B25"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B26"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B27","doi-asserted-by":"crossref","first-page":"14698.","DOI":"10.1038\/s41598-017-14413-w","article-title":"Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia","volume":"7","author":"Melong","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","article-title":"CDK4\/6 inhibitors in breast cancer therapy: current practice and future opportunities","volume":"191","author":"Lynce","year":"2018","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2131\/jts.40.339","article-title":"Aromatase knockout mice reveal an impact of estrogen on drug-induced alternation of murine electrocardiography parameters","volume":"40","author":"Kurokawa","year":"2015","journal-title":"J Toxicol Sci"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B30","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.3747\/co.25.4000","article-title":"Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines","volume":"25","author":"Matutino","year":"2018","journal-title":"Curr Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.2015.66.0803","article-title":"Definition of first-line endocrine therapy for hormone receptor-positive advanced breast cancer","volume":"34","author":"Reinert","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B32","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B33","doi-asserted-by":"crossref","first-page":"k3845.","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2013.10.014","article-title":"Toremifene for breast cancer: a review of 20 years of data","volume":"14","author":"Vogel","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B36","first-page":"1109","article-title":"A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood","volume":"3","author":"Pollack","year":"1997","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B37","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/84.23.1811","article-title":"High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine","volume":"84","author":"Trump","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B38","doi-asserted-by":"crossref","first-page":"H661","DOI":"10.1152\/ajpheart.00686.2002","article-title":"Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes","volume":"285","author":"He","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B39","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.bjp.0702730","article-title":"Effects of anion channel antagonists in canine colonic myocytes: comparative pharmacology of Cl-, Ca2+ and K+ currents","volume":"127","author":"Dick","year":"1999","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2015.01.048","article-title":"Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels","volume":"752","author":"Chae","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00210-003-0766-8","article-title":"Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen","volume":"368","author":"Thomas","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B42","first-page":"877","article-title":"The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes","volume":"287","author":"Liu","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9149(99)00193-9","article-title":"Effect of estrogen on ventricular repolarization in menopausal patients with syndrome X and effects of nicorandil","volume":"84","author":"Lee","year":"1999","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5122(00)00123-7","article-title":"Resting ECG is modified after oophorectomy and regresses with estrogen replacement therapy in premenopausal women","volume":"36","author":"De Leo","year":"2000","journal-title":"Maturitas"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0167-5273(00)00317-X","article-title":"Effects of progestin\u2013estrogen replacement therapy on QT-dispersion in postmenopausal women","volume":"75","author":"Haseroth","year":"2000","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1047-2797(03)00050-4","article-title":"A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: the atherosclerosis risk in communities study","volume":"13","author":"Carnethon","year":"2003","journal-title":"Ann Epidemiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1542-474X.2004.94580.x","article-title":"Estrogen and progestin use and the QT interval in postmenopausal women","volume":"9","author":"Kadish","year":"2004","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B48","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1021\/acs.jmedchem.7b01682","article-title":"Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer","volume":"61","author":"Tria","year":"2018","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molmed.2012.12.007","article-title":"Estrogen synthesis and signaling pathways during aging: from periphery to brain","volume":"19","author":"Cui","year":"2013","journal-title":"Trends Mol Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B50","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B51","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3747\/co.25.3735","article-title":"Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects","volume":"25","author":"Pistelli","year":"2018","journal-title":"Curr Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B52","doi-asserted-by":"crossref","first-page":"93.","DOI":"10.1186\/1477-7827-9-93","article-title":"Aromatase inhibitors in men: effects and therapeutic options","volume":"9","author":"de Ronde","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00682745","article-title":"Arimidex: a potent and selective fourth-generation aromatase inhibitor","volume":"30","author":"Plourde","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B54","first-page":"1060028018793656","article-title":"Review of cyclin-dependent kinase 4\/6 inhibitors for the treatment of hormone receptor-positive advanced breast cancer","author":"Hecht","year":"2018","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B55","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CAD.0000000000000589","article-title":"Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer","volume":"29","author":"Durairaj","year":"2018","journal-title":"Anticancer Drugs"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-3085-8","article-title":"Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer","volume":"78","author":"Fujiwara","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B58","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B59","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B60","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.2011.1791","article-title":"Androgen deprivation therapy and competing risks","volume":"306","author":"Kelly","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B62","first-page":"395","article-title":"Modulation by testosterone of an endogenous hERG potassium channel current","volume":"59","author":"Ridley","year":"2008","journal-title":"J Physiol Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B63","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1210\/en.2007-1802","article-title":"Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-a-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1\/2","volume":"149","author":"Wu","year":"2008","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ceca.2006.11.003","article-title":"Molecular requirements for L-type Ca2+ channel blockade by testosterone","volume":"42","author":"Scragg","year":"2007","journal-title":"Cell Calcium"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B65","doi-asserted-by":"crossref","first-page":"e0177532.","DOI":"10.1371\/journal.pone.0177532","article-title":"A mutation in the CACNA1C gene leads to early repolarization syndrome with incomplete penetrance: a Chinese family study","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-2952(01)00611-6","article-title":"Testosterone-mediated modulation of HERG blockade by proarrhythmic agents","volume":"62","author":"Shuba","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1113\/jphysiol.2002.030460","article-title":"Effect of androgen deficiency on mouse ventricular repolarization","volume":"546","author":"Brouillette","year":"2003","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cardiores.2004.09.012","article-title":"Sex and strain differences in adult mouse cardiac repolarization: importance of androgens","volume":"65","author":"Brouillette","year":"2005","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B69","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1096\/fj.15-278754","article-title":"Kcne4 deletion sex- and age-specifically impairs cardiac repolarization in mice","volume":"30","author":"Crump","year":"2016","journal-title":"FASEB J"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ceca.2006.09.003","article-title":"Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: acute actions antagonize chronic effects","volume":"41","author":"Er","year":"2007","journal-title":"Cell Calcium"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2010.04.014","article-title":"Chronic treatment with anabolic steroids induces ventricular repolarization disturbances: cellular, ionic and molecular mechanism","volume":"49","author":"Medei","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B72","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1748-1716.2011.02303.x","article-title":"Interaction of gonadal steroids and the glucocorticoid corticosterone in the regulation of the L-type Ca(2+) current in rat left ventricular cardiomyocytes","volume":"202","author":"Wagner","year":"2011","journal-title":"Acta Physiol (Oxf)"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B73","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/apha.12158","article-title":"Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats","volume":"209","author":"Eleawa","year":"2013","journal-title":"Acta Physiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/apha.12056","article-title":"The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction","volume":"208","author":"Marques Neto","year":"2013","journal-title":"Acta Physiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12576-016-0459-y","article-title":"Arrhythmogenic effect of androgens on the rat heart","volume":"67","author":"Argenziano","year":"2017","journal-title":"J Physiol Sci"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12576-017-0590-4","article-title":"Testosterone-mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats","volume":"68","author":"Masuda","year":"2018","journal-title":"J Physiol Sci"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B77","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.104.523217","article-title":"Nontranscriptional regulation of cardiac repolarization currents by testosterone","volume":"112","author":"Bai","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B78","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.94.6.1471","article-title":"Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart","volume":"94","author":"Drici","year":"1996","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B79","first-page":"1068","article-title":"Effects of gonadal steroids on ventricular repolarization and on the response to E4031","volume":"285","author":"Hara","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B80","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/01.CIR.103.17.2207","article-title":"Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs","volume":"103","author":"Pham","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B81","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000033596.21845.D8","article-title":"Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits","volume":"106","author":"Pham","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2605.2002.00349.x","article-title":"Effects of dihydrotestosterone on cardiac inward rectifier K(+) current","volume":"25","author":"Carnes","year":"2002","journal-title":"Int J Androl"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B83","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0008-6363(01)00449-7","article-title":"Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current","volume":"53","author":"Pham","year":"2002","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0008-6363(02)00673-9","article-title":"In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits","volume":"57","author":"Liu","year":"2003","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/fcp.12122","article-title":"Aldosterone and testosterone: two steroid hormones structurally related but with opposite electrophysiological properties during myocardial ischemia-reperfusion","volume":"29","author":"Alexandre","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1748-1716.2006.01618.x","article-title":"Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs","volume":"188","author":"Fulop","year":"2006","journal-title":"Acta Physiol (Oxf)"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B87","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ahj.2014.07.010","article-title":"Mechanisms of sex and age differences in ventricular repolarization in humans","volume":"168","author":"Vicente","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B88","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1113\/JP273142","article-title":"A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias","volume":"595","author":"Yang","year":"2017","journal-title":"J Physiol (Lond)"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B89","doi-asserted-by":"crossref","first-page":"57.","DOI":"10.1016\/S1569-9056(04)90218-7","article-title":"217 Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: results of three randomized controlled clinical studies","volume":"3","author":"Garnick","year":"2004","journal-title":"Eur Urol Suppl"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B90","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B91","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","article-title":"Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B92","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4236\/oju.2012.223029","article-title":"Changes in electrocardiogram findings during treatment with gonadotropin-releasing hormone agonist and surgical castration for prostate carcinoma","volume":"02","author":"Sa\u011flam","year":"2012","journal-title":"Open J Urol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-012-1916-9","article-title":"Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Tolcher","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B94","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","article-title":"Androgen deprivation therapy is associated with prolongation of QTC interval in men with prostate cancer","volume":"2","author":"Gagliano-Juca","year":"2018","journal-title":"J Endocr Soc"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B95","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.14168","article-title":"Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review","volume":"122","author":"Bolton","year":"2018","journal-title":"BJU Int"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B96","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B97","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.amjcard.2003.07.044","article-title":"Effect of testosterone therapy on QT dispersion in men with heart failure","volume":"92","author":"Malkin","year":"2003","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2265.2006.02715.x","article-title":"Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study","volume":"66","author":"Chung","year":"2007","journal-title":"Clin Endocrinol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B99","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.amjcard.2008.11.041","article-title":"Effects of testosterone on ventricular repolarization in hypogonadic men","volume":"103","author":"Charbit","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B100","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1111\/j.1365-2605.2009.00985.x","article-title":"Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: a pilot study","volume":"33","author":"Pecori Giraldi","year":"2010","journal-title":"Int J Androl"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B101","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1111\/j.1365-2605.2011.01163.x","article-title":"Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure","volume":"34","author":"Schwartz","year":"2011","journal-title":"Int J Androl"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000347070","article-title":"Testosterone replacement therapy improves QTaVI in hypogonadal men with spinal cord injury","volume":"97","author":"La Fountaine","year":"2013","journal-title":"Neuroendocrinology"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B103","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/pace.12580","article-title":"Short QTc interval in males with klinefelter syndrome-influence of CAG repeat length, body composition, and testosterone replacement therapy","volume":"38","author":"Jorgensen","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B104","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1210\/jc.2017-00196","article-title":"Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials","volume":"102","author":"Gagliano-Juca","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B105","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B106","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tranon.2016.08.001","article-title":"Association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer","volume":"9","author":"Campora","year":"2016","journal-title":"Transl Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B107","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/ijo.2015.3274","article-title":"Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways","volume":"48","author":"Grossebrummel","year":"2016","journal-title":"Int J Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B110","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B111","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Martin-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B112","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B113","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B114","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B116","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B117","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","article-title":"Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study","volume":"117","author":"Haque","year":"2017","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B118","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805022274700_cvz020-B119","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/878\/28283344\/cvz020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:03:56Z","timestamp":1694581436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/5\/878\/5304410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":119,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,1,30]]},"published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz020","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,1,30]]}}}